Recherche - Archive ouverte HAL Accéder directement au contenu

Filtrer vos résultats

125 résultats
Page :
triés par

Le Centre Pilote de suivi Biologique des Anticorps thérapeutiques (CePiBac) du CHU de Tours.

 Gilles Paintaud
6ème Réunion des Pharmacologues de l'Ouest. Mosnes, Jun 2008, MOSNES, France
Communication dans un congrès hal-00319009v1

Development of anti-infliximab antibodies increases infliximab clearance in chronic Inflammatory Bowel Diseases.

 David Ternant , Alexandre Aubourg , Charlotte Magdelaine-Beuzelin , Danielle Degenne , Hervé Watier , et al.
Immunogenicity for Biologics 2008, IBC Congress, Bâle (Suisse), 5-6 février., Feb 2008, BALE, Switzerland
Communication dans un congrès hal-00320459v1

Rituximab-related late-onset neutropenia in a severe rheumatoid arthritis patient (case report).

 H. Marotte , Gilles Paintaud , Hervé Watier , P. Miossec
Annals of the Rheumatic Diseases, 2008, 67, pp.893-894
Article dans une revue hal-00318083v1
Image document

Intra-tracheal amikacin spray delivery in healthy mechanically ventilated piglets

 Antoine Guillon , François Darrouzain , Nathalie Heuzé-Vourc'H , Antoine Petitcollin , Céline Barc , et al.
Pulmonary Pharmacology and Therapeutics, 2019, 57, pp.101807. ⟨10.1016/j.pupt.2019.101807⟩
Article dans une revue hal-02526680v1

Pharmacokinetics (PK) of mAbs

 Gilles Paintaud
Médecine/Sciences, 2009, 25 (12), pp.1057-1062
Article dans une revue hal-00616817v1

Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients

 Nicolas Azzopardi , Therry Lecomte , David Ternant , Michele Boisdron-Celle , Friedrich Piller , et al.
Fundamental & Clinical Pharmacology, 2011, 25, pp.34-34
Article dans une revue hal-00616314v1

Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis

 Hubert Marotte , Gilles Paintaud , Herve Watier , Pierre Miossec
Annals of the Rheumatic Diseases, 2008, 67 (6), pp.893-894
Article dans une revue hal-00616939v1
Image document

Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab

 Jérôme Rollin , Audrey Payancé , Valérie Gouilleux-Gruart , Michelle Boisdron-Celle , Nicolas Azzopardi , et al.
Pharmacogenomics, 2015, 16 (18), pp.2035-2043. ⟨10.2217/pgs.15.139⟩
Article dans une revue hal-02381189v1

Acute Lithium Intoxications, Review of the Literature and Cases Study.

 Corinne Schmitt , Yves Furet , Dominique Perrotin , Gilles Paintaud
Thérapie, 2009, 64 (1), pp.55-63
Article dans une revue hal-00616922v1

The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition

 Amina Bensalem , Guillaume Cartron , Ulrich Specks , Denis Mulleman , Emmanuel Gyan , et al.
Clinical Pharmacokinetics, 2022, 61 (3), pp.423-437. ⟨10.1007/s40262-021-01081-3⟩
Article dans une revue hal-03482193v1
Image document

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study.

 Mira Tout , Olivier Casasnovas , Michel Meignan , Thierry Lamy , Franck Morschhauser , et al.
Blood, 2017, 129 (19), pp.2616-2623. ⟨10.1182/blood-2016-10-744292⟩
Article dans une revue hal-01547802v1

The underlying inflammatory chronic disease influences infliximab pharmacokinetics

 Christophe Passot , Denis Mulleman , Theodora Bejan-Angoulvant , Alexandre Aubourg , Stephanie Willot , et al.
mAbs, 2016, 8 (7), pp.1407-1416. ⟨10.1080/19420862.2016.1216741⟩
Article dans une revue hal-01980816v1

Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease

 David Ternant , Zahir Berkane , Laurence Picon , Valérie Gouilleux-Gruart , Jean-Frédéric Colombel , et al.
Clinical Pharmacokinetics, 2015, 54 (5), pp.551-562. ⟨10.1007/s40262-014-0225-3⟩
Article dans une revue hal-02425490v1

Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial

 Emilie Ducourau , Theo Rispens , Marine Samain , Emmanuelle Dernis , Fabienne Le Guilchard , et al.
RMD Open : Rheumatic & Musculoskeletal Diseases, 2020, 6 (1), pp.e001047. ⟨10.1136/rmdopen-2019-001047⟩
Article dans une revue hal-02439716v1

Infliximab concentration is predictive of control of disease activity and maintenance of treatment in rheumatoid arthritis.

 Lin D. Chu Miow , Emilie Ducourau , Denis Mulleman , P. Emond , Denis Ternant , et al.
Annual European Congress of Rheumatology, Paris, 11-14 June 2008., Jun 2008, PARIS, France. Suppl. II:177 (THU-0131)
Communication dans un congrès hal-00320106v1

Adalimumab trough serum levels and clinical response in a single-center cohort of inflammatory bowel disease patients: Can trough serum levels serve as a predictor for Future Loss of Response?

 K. Karmiris , Gilles Paintaud , Danielle Degenne , M. Ferrante , Anne-Claire Duveau , et al.
Digestives Diseases Week San Diego 17-22 mai., May 2008, SAN DIEGO, United States. 134 (4, Supplement 1): A-68
Communication dans un congrès hal-00320142v1

Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis

 Theodora Bejan-Angoulvant , David Ternant , Fadela Daoued , Frédéric Medina , Louis Bernard , et al.
Arthritis & rheumatology, 2017, 69 (1), pp.108-113. ⟨10.1002/art.39841⟩
Article dans une revue hal-01980809v1

Development and validation of an enzyme-linked immunosorbent assay to measure adalimumab concentration

 Celine Desvignes , Soujanya Edupuganti , François Darrouzain , Anne-Claire Duveau , Amy Loercher , et al.
Bioanalysis, 2015, 7 (10), pp.1253-1260. ⟨10.4155/bio.15.30⟩
Article dans une revue hal-02372930v1
Image document

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study

 Benoit Coudert , Jean-Yves Pierga , Marie-Ange Mouret-Reynier , Kaldoun Kerrou , Jean-Marc Ferrero , et al.
EClinicalMedicine, 2020, 28, pp.100566. ⟨10.1016/j.eclinm.2020.100566⟩
Article dans une revue hal-03244169v1

An Enzyme-Linked Immunosorbent Assay to Study Bevacizumab Pharmacokinetics

 David Ternant , Nicolas Ceze , Thierry Lecomte , Danielle Degenne , Anne-Claire Duveau , et al.
Ther. Drug Monit., 2010, 32 (5), pp.647-652
Article dans une revue hal-00616329v1

An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab

 D. Ternant , N. Ceze , F. Piller , D. Degenne , E. Dorval , et al.
Fundamental & Clinical Pharmacology, 2009, 23, pp.23-23
Article dans une revue hal-00616413v1

Therapeutic antibodies in ophthalmology Old is new again

 Charlotte Magdelaine-Beuzelin , Coralie Pinault , Gilles Paintaud , Herve Watier
mAbs, 2010, 2 (2), pp.176-180. ⟨10.4161/mabs.2.2.11205⟩
Article dans une revue hal-00616362v1
Image document

Pharmacokinetics of adalimumab in Crohn’s disease

 David Ternant , Konstantinos Karmiris , Séverine Vermeire , Celine Desvignes , Nicolas Azzopardi , et al.
European Journal of Clinical Pharmacology, 2015, 71 (9), pp.1155-1157. ⟨10.1007/s00228-015-1892-1⟩
Article dans une revue hal-01769822v1

Aerosoltherapy for lung tumors using the monoclonal antibody cetuximab

 Agnes Maillet , Laurent Guilleminault , Nicolas Azzopardi , Jerome Montharu , Laurent Vecellio , et al.
Journal of Thoracic Oncology, 2009, 4 (9), pp.S600-S600
Article dans une revue hal-00616858v1

Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration

 David Ternant , Christophe Passot , Alexandre Aubourg , Philippe Goupille , Celine Desvignes , et al.
Clinical Pharmacokinetics, 2018, 57 (9), pp.1173-1184. ⟨10.1007/s40262-017-0621-6⟩
Article dans une revue hal-02372850v1
Image document

Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans

 David Ternant , Nicolas Azzopardi , William Raoul , Theodora Bejan-Angoulvant , Gilles Paintaud
Clinical Pharmacokinetics, In press, ⟨10.1007/s40262-018-0680-3⟩
Article dans une revue hal-01821717v1
Image document

A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial)

 Mario Campone , Thomas Bachelot , Isabelle Treilleux , Barbara Pistilli , Julia Salleron , et al.
European Journal of Cancer, 2021, 158, pp.169-180. ⟨10.1016/j.ejca.2021.09.017⟩
Article dans une revue hal-03469622v1

Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial

 Emilie Ducourau , Theo Rispens , Marine Samain , Emmanuelle Dernis , Fabienne Le Guilchard , et al.
RMD Open : Rheumatic & Musculoskeletal Diseases, 2020, 6 (1), pp.e001047. ⟨10.1136/rmdopen-2019-001047⟩
Article dans une revue hal-03244823v1

Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study

 Melanie Roland , Christelle Barbet , Gilles Paintaud , Charlotte Magdelaine-Beuzelin , Elisabeth Diot , et al.
Lupus, 2009, 18 (5), pp.441-447
Article dans une revue hal-00616925v1

Development and validation of an ELISA to study panitumumab pharmacokinetics

 Celine Desvignes , Christophe Passot , David Ternant , Morgane Caulet , Caroline Guérineau , et al.
Bioanalysis, 2018, 10 (4), pp.205-214. ⟨10.4155/bio-2016-0292⟩
Article dans une revue hal-02372863v1
Page :